H-Index
70
Scimago Lab
powered by Scopus
Clarivate
Analytics
Formerly the IP & Science
business of Thomson Reuters

Logo




eISSN: 1643-3750

Get your full text copy in PDF

Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: A review

Giuliano Rizzardini, Amedeo Capetti

Med Sci Monit 2006; 12(12): RA269-276

ID: 469713


The major trials conducted on treatment simplifi cation included large portions of patients who had previously received monotherapy or dual therapy and were likely to have relevant mutations of resistance at baseline. These studies concluded that simplifi cation was safe (especially when this
population was excluded), with some additional risk of viral failure for subjects simplifi ed to abacavir- based regimens. On the other hand, induction-maintenance studies and other studies which involved only patients who had started HAART as the fi rst-line showed that simplifi cation to abacavir
was as safe as continuation of the original regimen and better accepted by the patients. The largest randomized studies of simplifi cation that allowed extrapolation of data on the population of subjects who had never received suboptimal therapy were reviewed. Four studies failed to show signifi cant differences in effi cacy between treatment arms, while two detected signifi cant differences in favor of the continuation arms. Simplifi cation to abacavir led to signifi cant decreases in cholesterol and triglyceride levels and to slight improvements in quality of life. No variations in body shape were detected, although the duration was probably insuffi cient and most studies
did not involve adequate technology (i.e. DEXA, CT). Other, smaller studies are also presented in the review, selected for their particular design or analysis, which may contribute to a better understanding of the setting in which simplifi cation may be a feasible option. Choosing the adequate timing and the correct patient characteristics, simplifi cation to abacavirbased
regimens is safe and prevents metabolic consequences of therapy.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree